Information  X 
Enter a valid email address

Company Name matching 'uniQure Inc.'

Date
Time Source
Company
Announcement
23 Jun 2022 12:05 pm GNW   uniQure Inc. uniQure Announces Update on Low-Dose Cohort in Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
22 Jun 2022 9:34 pm GNW   uniQure Inc. CORRECTION -- uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
24 May 2022 1:00 pm GNW   uniQure Inc. uniQure Announces FDA Acceptance of Biologics License Application for Etranacogene Dezaparvovec under Priority Review
11 May 2022 12:05 pm GNW   uniQure Inc. uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 May 2022 9:45 pm GNW   uniQure Inc. uniQure Announces Multiple Presentations at Upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
  12:05 pm GNW   uniQure Inc. uniQure Announces First Quarter 2022 Financial Results and Highlights Recent Company Progress
21 Mar 2022 11:05 am GNW   uniQure Inc. uniQure Announces Completion of Patient Enrollment in the First Two Cohorts of its Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
25 Feb 2022 12:05 pm GNW   uniQure Inc. uniQure Announces 2021 Financial Results and Highlights Recent Company Progress
07 Feb 2022 12:05 pm GNW   uniQure Inc. uniQure Announces Dosing of First Patients in European Open-Label Clinical Trial of AMT-130 Gene Therapy in Huntington’s Disease
16 Dec 2021 12:00 pm GNW   uniQure Inc. uniQure Announces Clinical Update on First Patients in Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
09 Dec 2021 12:05 pm GNW   uniQure Inc. uniQure and CSL Behring Announce Primary Endpoint Achieved in HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with Hemophilia B
02 Nov 2021 11:05 am GNW   uniQure Inc. uniQure Announces Latest Positive Recommendation from Data Safety Monitoring Board in Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
01 Nov 2021 11:05 am GNW   uniQure Inc. uniQure to Participate in Upcoming Industry Conferences in November
25 Oct 2021 12:05 pm GNW   uniQure Inc. uniQure Announces Third Quarter 2021 Financial Results and Highlights Recent Company Progress
21 Oct 2021 2:30 pm GNW   uniQure Inc. uniQure Announces the Appointment of Rachelle Jacques to its Board of Directors
19 Oct 2021 12:05 pm GNW   uniQure Inc. uniQure Announces Presentations at the Annual Meeting of The European Society of Gene and Cell Therapy (ESGCT)
30 Sep 2021 12:05 pm GNW   uniQure Inc. uniQure to Participate in Multiple Upcoming Industry Conferences in October
07 Sep 2021 12:05 pm GNW   uniQure Inc. uniQure to Participate in Multiple Upcoming Industry Conferences in September
30 Aug 2021 12:05 pm GNW   uniQure Inc. uniQure Announces Completion of Additional Patient Procedures Following Positive Recommendation from Data Safety Monitoring Board in Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
26 Jul 2021 12:05 pm GNW   uniQure Inc. uniQure Announces Second Quarter 2021 Financial Results and Highlights Recent Company Progress
02 Jul 2021 2:00 pm GNW   uniQure Inc. uniQure Announces Presentations at Upcoming International Society on Thrombosis and Haemostasis (ISTH) Virtual Congress
22 Jun 2021 4:31 pm GNW   uniQure Inc. uniQure Announces Positive 52-Week Clinical Data from HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with Hemophilia B and Provides Regulatory Update
  4:31 pm GNW   uniQure Inc. uniQure to Acquire Corlieve Therapeutics and Advance its Gene Therapy Program to Treat Temporal Lobe Epilepsy (TLE)
16 Jun 2021 12:05 pm GNW   uniQure Inc. uniQure Announces Enrollment of First Two Patients in Second Cohort of Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
02 Jun 2021 3:31 pm GNW   uniQure Inc. UPDATE -- uniQure to Participate in Multiple Upcoming Industry Conferences in June
27 May 2021 12:05 pm GNW   uniQure Inc. uniQure Announces Positive Recommendation to Advance Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
13 May 2021 12:00 pm GNW   uniQure Inc. uniQure Presents HOPE-B Clinical Data Demonstrating Clinical Benefit in Hemophilia B Patients with Pre-existing Antibodies to AAV5 Vector
10 May 2021 12:05 pm GNW   uniQure Inc. uniQure Announces First Quarter 2021 Financial Results and Highlights Recent Company Progress
06 May 2021 12:00 pm GNW   uniQure Inc. uniQure announces closing of commercialization and license agreement with CSL Behring
03 May 2021 12:05 pm GNW   uniQure Inc. uniQure to Participate in Multiple Upcoming Industry Conferences in May
28 Apr 2021 12:05 pm GNW   uniQure Inc. uniQure Announces Presentations at Upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
26 Apr 2021 12:05 pm GNW   uniQure Inc. uniQure Announces FDA Removes Clinical Hold on Hemophilia B Gene Therapy Program
08 Apr 2021 12:05 pm GNW   uniQure Inc. uniQure Announces Publications of Preclinical Data for AMT-130 in Huntington’s Disease Showing Safety of Administration in NHPs and Widespread Long-Term HTT-Lowering in the Brain
05 Apr 2021 12:05 pm GNW   uniQure Inc. uniQure Announces Completion of Enrollment in First Cohort of Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
01 Apr 2021 12:05 pm GNW   uniQure Inc. uniQure to Participate in Multiple Upcoming Industry Conferences in April
29 Mar 2021 12:05 pm GNW   uniQure Inc. uniQure Announces Findings from Reported Case of Hepatocellular Carcinoma (HCC) in Hemophilia B Gene Therapy Program
01 Mar 2021 12:05 pm GNW Factsheet uniQure Inc. (0EE0) uniQure Announces 2020 Financial Results and Highlights Recent Company Progress
26 Feb 2021 12:05 pm GNW Factsheet uniQure Inc. (0EE0) uniQure to Participate in Multiple Upcoming Industry Conferences in March
01 Feb 2021 12:05 pm GNW Factsheet uniQure Inc. (0EE0) uniQure to Participate in Multiple Upcoming Industry Conferences in February
21 Dec 2020 12:05 pm GNW Factsheet uniQure Inc. (0EE0) uniQure Announces Clinical Update on Hemophilia B Gene Therapy Program
08 Dec 2020 12:00 pm GNW Factsheet uniQure Inc. (0EE0) uniQure Presents Late-Breaking Data from the HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with Hemophilia B at the 62nd Annual Meeting of the American Society of Hematology
07 Dec 2020 9:05 pm GNW Factsheet uniQure Inc. (0EE0) uniQure Announces Two-Year Follow-Up Data from the Phase IIb Study of Etranacogene Dezaparvovec and Long-Term Follow-Up Data for AMT-060 in Patients with Hemophilia B
30 Nov 2020 12:05 pm GNW Factsheet uniQure Inc. (0EE0) uniQure Announces Multiple Presentations and Investor Webcast on Hemophilia B Gene Therapy Program at the 62nd American Society of Hematology (ASH) Annual Meeting
19 Nov 2020 2:10 pm GNW Factsheet uniQure Inc. (0EE0) uniQure Announces Positive Top-Line Data from the HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with Hemophilia B
04 Nov 2020 3:46 pm GNW Factsheet uniQure Inc. (0EE0) uniQure Announces Clinical Data Presentations at the 62nd American Society of Hematology (ASH) Annual Meeting
  12:05 pm GNW Factsheet uniQure Inc. (0EE0) uniQure to Participate in Multiple Upcoming Industry Conferences in November
27 Oct 2020 11:05 am GNW Factsheet uniQure Inc. (0EE0) uniQure Announces Third Quarter 2020 Financial Results and Highlights Recent Company Progress
13 Oct 2020 12:05 pm GNW Factsheet uniQure Inc. (0EE0) uniQure Announces Enrollment of Next Two Patients in Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
30 Sep 2020 12:05 pm GNW Factsheet uniQure Inc. (0EE0) uniQure to Participate in Multiple Upcoming Industry Conferences in October
25 Sep 2020 12:05 pm GNW Factsheet uniQure Inc. (0EE0) uniQure Announces Recommendations from Data Safety Monitoring Board of Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
03 Sep 2020 12:05 pm GNW Factsheet uniQure Inc. (0EE0) uniQure to Participate in Multiple Upcoming Industry Conferences in September
26 Aug 2020 12:05 pm GNW Factsheet uniQure Inc. (0EE0) uniQure Announces Appointment of Ricardo Dolmetsch, Ph.D., as President, Research & Development
30 Jul 2020 12:05 pm GNW Factsheet uniQure Inc. (0EE0) uniQure Announces Second Quarter 2020 Financial Results and Highlights Recent Company Progress
24 Jun 2020 9:05 pm GNW Factsheet uniQure Inc. (0EE0) uniQure Announces License Agreement with CSL Behring to Commercialize Hemophilia B Gene Therapy
19 Jun 2020 12:05 pm GNW Factsheet uniQure Inc. (0EE0) uniQure Announces First Two Patients Treated in Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
17 Jun 2020 9:05 pm GNW Factsheet uniQure Inc. (0EE0) uniQure Announces the Appointment of Leonard E. Post, Ph.D. to its Board of Directors
15 Jun 2020 12:05 pm GNW Factsheet uniQure Inc. (0EE0) uniQure Announces Change for its 2020 Annual General Meeting of Shareholders
14 May 2020 12:00 pm GNW Factsheet uniQure Inc. (0EE0) uniQure Presents New Preclinical Data in SCA3, Fabry Disease, and Hemophilia A at the ASGCT Annual Meeting


Company Announcements Archive »


a d v e r t i s e m e n t